Tempus AI responded that the report was "riddled with hypotheticals and inaccuracies and fails to address Tempus’ history of ...

In an exciting development for Tempus AI (NasdaqGS:TEM), the company experienced a significant 51% increase in its share price over the last quarter. This surge coincides with major events including ...

Tempus AI surges 12.5% on new AI tools, a $200M AstraZeneca deal, and clinical data expansion- but is it time to buy?

Tempus AI Inc. misled investors about the worth of its deals and artificial intelligence abilities, obscuring weaknesses with ...

Tempus will use its "Lens" data analytics platform to analyze and restructure genomic data from the the Abrams Research Center.

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Tempus AI, Inc. ("Tempus" or "the Company") (NASDAQ: TEM) for violations of §§10 ...

Based on its analysis, Spruce Point stated that Tempus AI stock has the potential to fall about 50% to 60%. From the stock's closing price on Tuesday (the day before Spruce Point released its report), ...

TEM is a data-rich platform that recently clinched a $200 million deal with AstraZeneca. TEM’s main bet is now on AI for ...

While large language models have been the primary focus of Wall Street, the real asymmetric returns for savvy growth ...